EU-SolidAct is part of the EU-RESPONSE project who has received funding from the European Union’s Horizon 2020 Research and Innovation Program under grant agreement No 101015736. @EUScienceInnov
DMC/DSMB members do very valuable and mostly unappreciated work in RCTs. Thank you very much drs. @stefano_vella, Du, Medaglini, Jacobs, vd Werf, Medaglini, @pocock_stuart, @phaikyeong, Barnes, Yeni and Collier for excellent work in our DMC!
We’re pleased to announce that our lead candidate, #bemcentinib, has been selected for inclusion in a pan-European research project exploring potential treatments for hospitalised COVID-19 patients, the @EU_SolidAct trial.
Read the release here: bergenbio.com/investors/stoc…#AXL
New paper from the DisCoVeRy and the @EU_SolidAct EU-RESPONSE group with @DKFBasel contribution by Matthias Briel: "Europe, despite its diversity, must be capable of responding unanimously and rapidly to any health crisis": bit.ly/3HPM3yE#platformtrial#COVID19
Baricitinib/placebo has arrived @LovisenbergSH! @simenws and colleagues are ready to include their first patient in the Trial as the eight European site.
Den nye Europeiske plattformstudien for COVID-19 og fremtidige pandemier, EU-SolidAct, har nå startet å inkludere pasienter ved norske sykehus. Studien skal gå i 15 land og ledes av OUS. bit.ly/EU_SolidAct /
@EU_SolidAct / @ECRIN_ERIC / @Inserm/ @EUScienceInnov
EU SolidAct, a new platform trial for emerging pandemics, today starts testing new drugs for severe COVID-19, aiming to improve treatment options and to strengthen European pandemic preparedness bit.ly/EU_SolidAct / @EU_SolidAct / @ECRIN_ERIC / @Inserm / @EUScienceInnov